Cartilage Oligomeric Matrix Protein (COMP) in systemic sclerosis (SSc): Role in disease severity and subclinical rheumatoid arthritis overlap

被引:24
|
作者
Gheita, Tamer A. [1 ]
Hussein, Hani [1 ]
机构
[1] Cairo Univ, Fac Med, Dept Chem Pathol, Cairo, Egypt
关键词
Systemic sclerosis; COMP; RA overlap; CYCLIC CITRULLINATED PEPTIDE; CLASSIFICATION CRITERIA; JOINT INVOLVEMENT; AMERICAN-COLLEGE; ANTIBODIES; FEATURES; ARTHROPATHY; PREVALENCE; DETECT;
D O I
10.1016/j.jbspin.2011.02.022
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective: The aim of the present study was to compare the serum level of COMP in both subsets of Systemic sclerosis (SSc) as a marker of arthritis and reveal an associated subclinical RA overlap and a relation to clinical, laboratory and radiological findings in SSc. Methods: Forty adult SSc patients were included in the study and grouped into the two subsets diffuse (dSSc) and limited (lSSc) SSc. Their mean age was 40 +/- 9 years. Thorough history taking and clinical examination were performed to all patients. Skin thickness was scored according to the modified Rodnan skin score method (MRSS). The disease activity was assessed by measuring the Medsger severity score. The joints were extensively examined and the tenderness counted according to the Ritchie articular index (RAI). Relevant laboratory and radiological investigations were carried out. The serum COMP level was determined by ELISA. Results: The serum COMP was significantly higher in the SSc patients compared to the control and obviously higher in the dSSc compared to the lSSc patients. The level of COMP was higher in the females and significantly higher in the SSc patients with arthritis (56.5 +/- 6.8 ug/ml) compared to those without (34 +/- 8.3 ug/ml) (P 0.000). Conclusion: The COMP level may become a nonspecific but useful marker for joint involvement in SSc patients to identify patients at risk of joint damage and developing SSc-RA overlap syndrome even with mild arthritis. (C) 2011 Societe francaise de rhumatologie. Published by Elsevier Masson SAS. All rights reserved.
引用
收藏
页码:51 / 56
页数:6
相关论文
共 50 条
  • [21] Human synovial B-cell hybridoma from rheumatoid arthritis with specificity for cartilage oligomeric matrix protein (COMP).
    Souto-Carneiro, MM
    Krenn, V
    Muller, EC
    Hermann, R
    Otto, A
    Hensel, F
    Berek, C
    Konig, A
    Muller-Hermelink, HK
    ARTHRITIS AND RHEUMATISM, 1999, 42 (09): : S178 - S178
  • [22] Cartilage oligomeric matrix protein (COMP) has a dual role in complement regulation
    Happonen, K. E.
    Pramhed, A.
    Heinegard, D.
    Blom, A. M.
    MOLECULAR IMMUNOLOGY, 2009, 46 (14) : 2829 - 2829
  • [23] Serum levels of cartilage oligomeric matrix protein (COMP-TSP-5) in patients with rheumatoid arthritis stratified for functional class
    De Andrade, Fernanda Duarte
    Bender, Ana Ligia
    Da Silveira, Ines Guimaraes
    Stein, Helga
    Von Muhlen, Carlos Alberto
    Staub, Henrique Luiz
    SCIENTIA MEDICA, 2008, 18 (04) : 154 - 159
  • [24] Role of cartilage oligomeric matrix protein (COMP) as a prognostic biomarker in follow-up of early rheumatoid arthritis patients: Correlation to musculoskeletal ultrasonographic findings
    Hussein, Dahlia A.
    El Bakry, Samah A.
    Morshedy, Nashwa A.
    Ibrahim, Soha E.
    Sakr, Hossam Moussa
    Abo-Shady, Rania A.
    EGYPTIAN RHEUMATOLOGIST, 2018, 40 (04): : 221 - 226
  • [25] Analysis of cartilage oligomeric matrix protein (COMP) degradation and synthesis in equine joint disease
    Arai, K
    Misumi, K
    Carter, SD
    Shinbara, S
    Fujiki, M
    Sakamoto, H
    EQUINE VETERINARY JOURNAL, 2005, 37 (01) : 31 - 36
  • [26] Cartilage oligomeric matrix protein-induced complement activation in systemic sclerosis
    Otteby, Kaisa E.
    Holmquist, Emelie
    Saxne, Tore
    Heinegard, Dick
    Hesselstrand, Roger
    Blom, Anna M.
    ARTHRITIS RESEARCH & THERAPY, 2013, 15 (06)
  • [27] Cartilage oligomeric matrix protein-induced complement activation in systemic sclerosis
    Kaisa E Otteby
    Emelie Holmquist
    Tore Saxne
    Dick Heinegård
    Roger Hesselstrand
    Anna M Blom
    Arthritis Research & Therapy, 15
  • [28] Serum levels of cartilage oligomeric matrix protein (COMP): a rapid decrease in patients with active rheumatoid arthritis undergoing intravenous steroid treatment
    M. Skoumal
    G. Haberhauer
    J. Feyertag
    E. M. Kittl
    K. Bauer
    A. Dunky
    Rheumatology International, 2006, 26 : 1001 - 1004
  • [29] Serum levels of cartilage oligomeric matrix protein (COMP): a rapid decrease in patients with active rheumatoid arthritis undergoing intravenous steroid treatment
    Skoumal, M.
    Haberhauer, G.
    Feyertag, J.
    Kittl, E. M.
    Bauer, K.
    Dunky, A.
    RHEUMATOLOGY INTERNATIONAL, 2006, 26 (11) : 1001 - 1004
  • [30] Response of Cartilage Oligomeric Matrix Protein to Monoclonal Antibody Drugs in Patients with Rheumatoid Arthritis
    Tampoia, Marilina
    Brescia, Vincenzo
    Falappone, Paola
    Zucano, Antonietta
    Scioscia, Crescenzo
    Fontana, Antonietta
    Iannone, Florenzo
    Di Serio, Francesca
    Lapadula, Giovanni
    LABMEDICINE, 2009, 40 (11): : 645 - 650